查确定了氧化-4-碳胺KB-2777在体外表现出抗冠状病毒活性
Bud Jung1, Woonsung Na2, Minjoo Yeom3
1Department of Pharmacy, College of Pharmacy, Korea University, Sejong 30019, Republic of Korea.
Pharmaceutics
|November 27, 2025
概括
新型抗病毒KB-2777对包括SARS-CoV-2变种在内的α和β冠状病毒具有广泛的体外活性. 当与现有的直接作用抗病毒药物 (DAA) 结合时,它显示出有前途的协同效应添加剂.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 免疫学 免疫学 免疫学
背景情况:
- 直接作用抗病毒药物 (DAA) 呈现出血统特异性的活性,容易迅速发展耐药性.
- 氧-4-碳胺化合物KB-2777被确定为广泛的冠状病毒抑制的有希望的头.
研究的目的:
- 描述KB-2777对α和β冠状病毒的体外抗病毒活性.
- 为了确定KB-2777.7的添加时间 (TOA) 配置和主机响应签名.
- 为了评估KB-2777与基准DAA的结合性.
主要方法:
- KB-2777对HCoV-NL63,HCoV-OC43和PEDV进行了测试,量化了病毒RNA,病毒载量 (TCID50) 和细胞病变效应 (CPE).
- 添加时间实验评估了不同治疗时间 (感染前,同时,感染后) 的抑制.
- 使用ZIP分数评估了与涅马特里尔维尔和GS-441524的组合; 宿主反应转录被描述.
主要成果:
- 在测试的冠状病毒中,KB-2777表现出强大的抗病毒活性,EC50值在1.59至5.27μM之间.
- 该化合物在治疗后表现出显著的活性,感染后48-72小时观察到明显的抑制.
- 与尼马特里尔维尔和GS-441524的组合显示了对协同效应的添加 (ZIP分数分别为5.16和8.40).
- 在感染细胞中KB-2777调节了宿主反应转录,包括IL6,IFNB1和ISG15.
结论:
- KB-2777在阿尔法和β系中显示可复制的基于细胞的抗冠状病毒活性.
- 它的TOA概况表明了早期进入后的主机调制机制.
- KB-2777与基准DAA兼容,支持进一步开发冠状病毒治疗.
相关概念视频
Antimicrobial Effectiveness
885
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
885
Subviral Agents
485
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
485
Antiepileptic Drugs: Potassium Channel Activators
613
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
613


